These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

72 related items for PubMed ID: 3207948

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Urinary galactosyl-hydroxylysine in postmenopausal osteoporotic women: A potential marker of bone fragility.
    Lo Cascio V, Bertoldo F, Gambaro G, Gasperi E, Furlan F, Colapietro F, Lo Cascio C, Campagnola M.
    J Bone Miner Res; 1999 Aug; 14(8):1420-4. PubMed ID: 10457275
    [Abstract] [Full Text] [Related]

  • 3. Urinary beta-1-galactosyl-0-hydroxylysine (GH) as a marker of collagen turnover of bone.
    Moro L, Pozzi Mucelli RS, Gazzarrini C, Modricky C, Marotti F, de Bernard B.
    Calcif Tissue Int; 1988 Feb; 42(2):87-90. PubMed ID: 3127029
    [Abstract] [Full Text] [Related]

  • 4. A study of osteoporosis as it relates to metabolic manifestations in edentulous women.
    Rodriquez GP, Claus-Walker J, Reed G.
    J Oral Implantol; 1992 Feb; 18(4):379-82. PubMed ID: 1298822
    [Abstract] [Full Text] [Related]

  • 5. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women.
    Garnero P, Delmas PD.
    J Musculoskelet Neuronal Interact; 2004 Mar; 4(1):50-63. PubMed ID: 15615078
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis.
    Bettica P, Taylor AK, Talbot J, Moro L, Talamini R, Baylink DJ.
    J Clin Endocrinol Metab; 1996 Feb; 81(2):542-6. PubMed ID: 8636265
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Use of clinical risk factors in elderly women with low bone mineral density to identify women at higher risk of hip fracture: The EPIDOS prospective study.
    Dargent-Molina P, Douchin MN, Cormier C, Meunier PJ, Bréart G, EPIDOS Study Group.
    Osteoporos Int; 2002 Jul; 13(7):593-9. PubMed ID: 12111021
    [Abstract] [Full Text] [Related]

  • 10. Urine products of bone breakdown as markers of bone resorption and clinical usefulness of urinary hydroxyproline: an overview.
    Simsek B, Karacaer O, Karaca I.
    Chin Med J (Engl); 2004 Feb; 117(2):291-5. PubMed ID: 14975218
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A rapid and simple method for quantitation of urinary hydroxylysyl glycosides, indicators of collagen turnover, using liquid chromatography/tandem mass spectrometry.
    Casetta B, Romanello M, Moro L.
    Rapid Commun Mass Spectrom; 2000 Feb; 14(23):2238-41. PubMed ID: 11114034
    [Abstract] [Full Text] [Related]

  • 13. [Absolute risk for fracture and WHO guideline. Bone turnover markers as predictive factors for osteoporotic fractures].
    Yoshimura N, World Health Organization.
    Clin Calcium; 2007 Jul; 17(7):1049-57. PubMed ID: 17607072
    [Abstract] [Full Text] [Related]

  • 14. Assessment of four biochemical markers of bone metabolism in postmenopausal osteoporosis.
    Majkić-Singh N, Ilić M, Ignjatović S, Aleksandra-Postić-Grujin.
    Clin Lab; 2002 Jul; 48(7-8):407-13. PubMed ID: 12146575
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Epidemiology, etiology, and diagnosis of osteoporosis.
    Lane NE.
    Am J Obstet Gynecol; 2006 Feb; 194(2 Suppl):S3-11. PubMed ID: 16448873
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.